Effects of doxycycline on progression of osteoarthritis - Results of a randomized, placebo-controlled, double-blind trial

被引:201
|
作者
Brandt, KD
Mazzuca, SA
Katz, BP
Lane, KA
Buckwalter, KA
Yocum, DE
Wolfe, F
Schnitzer, TJ
Moreland, LW
Manzi, S
Bradley, JD
Sharma, L
Oddis, CV
Hugenberg, ST
Heck, LW
机构
[1] Indiana Univ, Sch Med, Div Rheumatol, Indianapolis, IN 46202 USA
[2] Univ Arizona, Tucson, AZ USA
[3] Arthritis Res Ctr Fdn, Wichita, KS USA
[4] Northwestern Univ, Chicago, IL 60611 USA
[5] Univ Alabama Birmingham, Birmingham, AL USA
[6] Univ Pittsburgh, Pittsburgh, PA 15260 USA
来源
ARTHRITIS AND RHEUMATISM | 2005年 / 52卷 / 07期
关键词
D O I
10.1002/art.21122
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. To confirm preclinical data suggesting that doxycycline can slow the progression of osteoarthritis (OA). The primary outcome measure wag joint space narrowing (JSN) in the medial tibiofemoral compartment.. Methods. In this placebo-controlled trial, obese women (n = 431) ages 45-64 years with unilateral radiographic knee OA were randomly assigned to receive 30 months of treatment. with 100 mg doxycycline or placebo twice a day. Tibiofemoral JSN Was measured manually in fluoroscopically standardized radiographic examinations performed at baseline, 16 months, and 30 months. Severity of joint pain was recorded at 6-month intervals. Results. Seventy-one percent of all randomized subjects completed the trial. Radiographs were obtained from 85% of all randomized subjects at 30 months. Adherence to the dosing regimen was 91.8% among subjects who completed the study per protocol. After 16 months of treatment, the mean SD loss of joint space width in the index knee in the doxycycline group was 40% less than that in the placebo group (0.15 +/- 0.42 mm versus 0.24 +/- 0.54 mm); after 30 months, it was 33% less (0.30 +/- 0.60 mm versus 0.45 +/- 0.70 mm). Doxycycline did not reduce the mean severity of joint pain, although pain scores in both treatment groups were low at baseline and remained low throughout the trial, suggesting the presence of a floor effect. However, the frequency of followup visits at which the subject reported a >= 20% increase in pain in the index knee, relative to the previous visit, was reduced among those receiving doxycycline. In contrast, doxycycline did not have an effect on either JSN or pain in the contralateral knee. In both treatment groups, subjects who reported a >= 20% increase in knee pain at the majority of their followup visits had more rapid JSN than those whose pain did not increase. Conclusion. Doxycycline slowed the rate of JSN in knees with established OA. Its lack of effect on JSN in the contralateral knee suggests that pathogenetic mechanisms in that joint were different from those in the index knee.
引用
收藏
页码:2015 / 2025
页数:11
相关论文
共 50 条
  • [41] NALOXONE AMELIORATES THE PRURITUS OF CHOLESTASIS - RESULTS OF A DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED TRIAL
    BERGASA, NV
    ALLING, DW
    TALBOT, TL
    SWAIN, MG
    FRIED, MW
    FONG, TL
    YURDAYDIN, C
    SCHMITT, JM
    WALKER, EC
    TURNER, ML
    JONES, EA
    HEPATOLOGY, 1992, 16 (04) : A152 - A152
  • [42] Antithrombin therapy for severe preeclampsia: Results of a double-blind, randomized, placebo-controlled trial
    Maki, M
    Kobayashi, T
    Terao, T
    Ikenoue, T
    Satoh, K
    Nakabayashi, M
    Sagara, Y
    Kajiwara, Y
    Urata, M
    THROMBOSIS AND HAEMOSTASIS, 2000, 84 (04) : 583 - 590
  • [43] Results of a randomized, double-blind, placebo-controlled trial of lorcaserin in cocaine use disorder
    McCann, David J.
    Chen, Hegang H.
    Devine, Eric G.
    Gyaw, Shwe
    Ramey, Tatiana
    DRUG AND ALCOHOL DEPENDENCE, 2024, 255
  • [44] Inhalation aromatherapy during radiotherapy: Results of a placebo-controlled double-blind randomized trial
    Graham, PH
    Browne, L
    Cox, H
    Graham, J
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) : 2372 - 2376
  • [45] Establishing optimal selenium status: results of a randomized, double-blind, placebo-controlled trial
    Hurst, Rachel
    Armah, Charlotte N.
    Dainty, Jack R.
    Hart, Dave J.
    Teucher, Birgit
    Goldson, Andrew J.
    Broadley, Martin R.
    Motley, Amy K.
    Fairweather-Tait, Susan J.
    AMERICAN JOURNAL OF CLINICAL NUTRITION, 2010, 91 (04): : 923 - 931
  • [46] Methotrexate in Crohn's disease: Results of a randomized, double-blind, placebo-controlled trial
    Arora, S
    Katkov, W
    Cooley, J
    Kemp, JA
    Johnston, DE
    Schapiro, RH
    Podolsky, D
    HEPATO-GASTROENTEROLOGY, 1999, 46 (27) : 1724 - 1729
  • [47] Treatment of early rheumatoid arthritis with minocycline or placebo - Results of a randomized, double-blind, placebo-controlled trial
    ODell, JR
    Haire, CE
    Palmer, W
    Drymalski, W
    Wees, S
    Blakely, K
    Churchill, M
    Eckhoff, PJ
    Weaver, A
    Doud, D
    Erikson, N
    Dietz, F
    Olson, R
    Maloley, P
    Klassen, LW
    Moore, GF
    ARTHRITIS AND RHEUMATISM, 1997, 40 (05): : 842 - 848
  • [48] A randomized, double-blind, placebo-controlled trial: Paroxetine controlled release in fibromyalgia
    Patkar, AA
    Masand, PS
    Jiang, W
    Krulewicz, S
    Dube, E
    Purcell, C
    McMorran, C
    Peindl, K
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2004, 14 : S319 - S320
  • [49] Effects of Omeprazole on Sleep Disturbance: Randomized Multicenter Double-Blind Placebo-Controlled Trial
    Aimi, Masahito
    Komazawa, Yoshinori
    Hamamoto, Naoharu
    Yamane, Yuko
    Furuta, Koichiro
    Uchida, Yasushi
    Yano, Shozo
    Morita, Miwa
    Oguro, Hiroaki
    Miyake, Tatsuya
    Sugimoto, Toshitsugu
    Nagi, Seiichi
    Naora, Kohji
    Goubaru, Yoshiyuki
    Ishihara, Shunji
    Kinoshita, Yoshikazu
    CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 2014, 5
  • [50] Effects of ETyrosine on Parkinson's Disease: A Randomized, Double-Blind, Placebo-Controlled Trial
    DiFrancisco-Donoghue, Joanne
    Rabin, Ely
    Lamberg, Eric M.
    Werner, William G.
    MOVEMENT DISORDERS CLINICAL PRACTICE, 2014, 1 (04): : 348 - 353